cyrilzakka/clinical-trials huggingface dataset:
The Safety and Efficacy of 1064-nm Picosecond Laser With Microlens Array for Pore Tightening; a Pilot Study

The objective of this study is to evaluate the safety and efficacy of 1064-nm Picosecond laser 1064 With Microlens Array for Pore tightening.

The Safety and Efficacy of Picosecond laser 1064 Nanometers With Microlens Array for Pore tightening; a Pilot Study Primary outcome : pore size Secondary outcome : side effect, patient satisfaction, global evaluation the patient recieved laser treament once a month for 3 months and then follow up after last treatment at 1, 3 ,6 month

Enlarged facial pores is one of the skin signs in photoaging. There are 3 major clinical causes of enlarged facial pores: highs sebum excretion, decreased elasticity around pores and increased hair follicle volume. Possible causative factors of enlarged facial pores include many exogenous and endogenous factors include genetic predisposition, seborrhea and chronic ultraviolet light exposure. Picosecond laser are new device which has been used in skin rejuvenation. The main mechanism of action is laser induced optical breakdown (LIOB).

Eligibility Criteria:
Inclusion Criteria:

* Both male and female age 25-40 years
* No underlying disease

Exclusion Criteria:

* History of retinoid or other keratolytic drugs used within 6 months before enrolled
* History of keloid
* photosensitivity
* Immunocompromised host
Objective Diagnostic Markers and Personalized Intervention in MDD Patients

Major depressive disorder (MDD) is one of the most common psychiatric disorders, with high recurrence rate, suicide rate and disability rate. It's reported that the global burden caused by MDD will be up to the second rank among all the disease burdens by 2020. China is also confronted with the daunting challenges against MDD. It's assessed that the monthly incidence of MDD is 6.1%, non-hospitalizing rate reaches up to 92% and the non-treatment rate is approximate 95%. However, to date, the pathogenesis of MDD is obscure and the current therapies don't work well. Therefore, it's urgent and critical to elucidate the pathogenesis of MDD, to develop early diagnostic criteria and effective intervention in MDD. Considering the diversity of weights on genetic factor and environmental factor in MDD, in this project, the investigators aim firstly to explore the effect of "genetic-environmental interaction"on the pathogeny of MDD for classifying MDD into "genetic type", "environmental type" and "others" based on a case-control study. We next conduct the neurobiological, neurocognitive and psycho-behavioral assessments among MDD, schizophrenia and healthy groups to screen the salient endophenotypes for establishing the diagnostic models of MDD . The investigators further analyse the changes of these indicators after 8 weeks'medication to select the potential predictors for therapeutic evaluations and interventional options in MDD patients. Finally, the investigators continue a 2-year follow-up study to test and verify the predictors of prognosis in MDD patients.


Eligibility Criteria:
1. For MDD group:

   Inclusion criteria:
   * Age between 18-55, male or female;
   * The diagnosis of MDD consistent with DSM-IV (M.I.N.I)
   * First-episode or relapsed;
   * Certain ability of reading and writing to complete the questionnaire survey and psychological assessment.
   * All participants provide written confirmation of informed consent prior to engaging the study protocol.

   Exclusion criteria:
   * Current psychopathology or a history of neurologic conditions, including alcohol/substances dependence, the diagnosis of cognition impairment;
   * Severe somatic diseases, such as severe cardio-cerebral vascular diseases, respiratory diseases, liver diseases, kidney diseases, or malignant tumors;
   * Not signed the informed consent;
   * Been engaging other studies.
2. For Healthy control group

Inclusion criteria:

* age between 18 and 55 years at the time of enrollment;
* providing written confirmation of informed consent prior to engaging the study.

Exclusion criteria:

* lifetime or current diagnosis of any mental diseases;
* severe somatic diseases, such as severe cardio-cerebral vascular diseases, respiratory diseases, liver diseases, kidney diseases, or malignant tumors;
* not signed the informed consent;
* been engaging other studies.
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

This open-label study will assess the efficacy and safety of Tarceva (Erlotinib) in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who have not received previous chemotherapy for their disease and who present epidermal growth factor receptor mutations. Patients will receive Tarceva 150 mg orally daily until disease progression or unacceptable toxicity occurs.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Locally advanced (Stage IIIB), metastatic (Stage IV) or recurrent non-small cell lung cancer with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR)
* At least one measurable lesion according to RECIST criteria
* European Cooperative Oncology Group (ECOG) performance status 0-2
* Adequate hematological, liver and renal function
* Patients with stable cerebral metastases who have received surgical or radiotherapy will be eligible

Exclusion Criteria:

* Previous chemotherapy or therapy against EGFR for metastatic disease (neoadjuvant or adjuvant therapy after radical surgery is allowed if finalized \>/= 6 months before entering the study)
* History of another neoplasm except for carcinoma in situ of the cervix, adequately treated basal cell skin carcinoma, radically treated prostate carcinoma with good prognosis (Gleason \</= 6), or another curatively treated neoplasm without evidence of disease in the last 5 years
* Symptomatic cerebral metastases
* Any significant ophthalmologic abnormality
* Use of coumarins
* Pregnant or breast-feeding women
* Pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis and carcinomatosis (if this is the only presence of the disease)
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).

The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.

The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.


Eligibility Criteria:
Inclusion Criteria:

Age:

1. The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is \>=19 years of age.

   Disease Characteristics:
2. The participant has had signs and symptoms consistent with PsA for at least 3 months.
3. The participant meets the Classification Criteria for Psoriatic Arthritis (CASPAR criteria).
4. The participant has active arthritis as shown by a minimum of \>=3 tender joints in TJC68 and \>=3 swollen joints in SJC66 at the screening and baseline (Day 1) visits.
5. The participant has at least 1 active lesion of plaque PsO \>=2 cm in diameter, or any nail or nail bed changes characteristic of PsO.

   Medications for PsA:
6. The participant has had at least one of the following:

   1. Inadequate response to a nonsteroidal anti-inflammatory drug (NSAID), OR
   2. Inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD).

Exclusion Criteria:

PsA and PsO:

1. The participant has other disease(s) that might confound the evaluations of benefit of zasocitinib therapy, including but not limited to rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia.
2. The participant has a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).
Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).


Eligibility Criteria:
Main Inclusion Criteria:

* Patients must have the below proven, probable or possible deep mycosis;

  1. invasive aspergillosis
  2. chronic pulmonary aspergillosis
  3. mucormycosis
  4. cryptococcosis
* Female patients must be non-lactating and at no risk for pregnancy.

Main Exclusion Criteria:

* Women who are pregnant or breastfeeding.
* Patients with hypersensitivity to any of the components of the azole class of antifungals or the investigational product.
* Patients at high risk for QT/QTc prolongation, or patients with risk factors for torsades de pointes, or taking concomitant medications known to prolong the QT/QTc interval.
* Patients with a history of short QT syndrome.
* Patients with liver dysfunction at enrollment.
* Patients with moderate to severe kidney dysfunction at enrollment.
* Patients who receive prohibited concomitant drugs.
* Patients with any other fungal infection other than Aspergillus species, order Mucorales, or Cryptococcus species.
* Patients who are not expected to survive study duration.
* Patients with an underlying disease, complication or general condition that would complicate safety and efficacy evaluations.
* Patients with a history of taking voriconazole for deep mycosis and showing no response to this treatment.
* Patients taking systemic antifungals who are unable to stop taking these drugs during the study, or who are showing signs of improvement in their symptoms of deep mycosis as a result of these drugs.
Residual Neuromuscular Blockade in Cardiac Surgery Patients

The purpose of this project is to determine if reversal of neuromuscular blockade in cardiac surgery patients expedites time to extubation in fast track patients.

Neuromuscular blocking agents are used as part of most general anesthetics to help facilitate tracheal intubation and optimal surgical conditions (Barish et al). These medications cause universal paralysis of patients while unconscious. After most surgeries where extubation is planned, the standard of care is to "reverse" any residual neuromuscular blockade with either anticholinesterase treatment (specifically neostigmine) or sugammadex. Despite adequate reversal, residual neuromuscular blockade is a common problem seen in the post-anesthetic care unit (PACU). It leads to issues of airway obstruction, hypoxemia, respiratory complications including atelectasis and pneumonia and muscle weakness (Brull et al). The investigators posit that these complications are likely amplified in patients who require post-operative intensive care unit admission. In particular, the investigators hypothesize that cardiac surgery patients are at risk. Elective cardiac surgery patients are routinely admitted to the CVICU still intubated and ventilator-dependent immediately following surgery. The goal of uncomplicated cardiac surgery patients (fast track cardiac surgery patients) is to extubate them within 6 hours of ICU arrival. However, standard of care throughout the US does not include reversal of their neuromuscular blockade. By the time these patients meet extubation criteria, most providers believe that the neuromuscular blockade should have worn off and therefore do not administer reversal (Murphy et al). The investigators hypothesize that residual neuromuscular blockade delays time to extubation and increases respiratory complications in fast track cardiac surgery patients. By administering reversal of neuromuscular blockade in patients with a Train Of Four ratio of \<0.9 we anticipate that there will be an increase from 60 to 85% of patients being successfully extubated within 6 hours of arrival to the ICU and a decrease in composite respiratory complications.

Eligibility Criteria:
Inclusion Criteria:

* All outpatients \>18 years of age scheduled for elective coronary artery bypass graft surgery (CABG), aortic valve replacement (AVR), or combination CABG/AVR

Exclusion Criteria:

* Chronic kidney disease stage IV or V
* Liver disease, defined as AST, ALT or ALP \> 1.5x upper limit of normal Inpatient status
* Allergy to rocuronium
Swiss Chiropractic Cohort (Swiss ChiCo) Study: A Nationwide Practice-Based Research Network Project

The Swiss chiropractic cohort (Swiss ChiCo) practice-based research network (PBRN) is nationwide research project with the aim to develop a musculoskeletal focused PBRN within the Swiss chiropractic setting and describe the characteristics of clinicians recruited. Development of the PBRN has been guided through participatory engagement of multiple stakeholders including patients, clinicians, scientists, and policymakers.

Management of musculoskeletal (MSK) conditions is moving away from traditional medical treatments such as pain medication and towards more physical and preventative approaches. As a result, there is a need to describe manual care approaches to make informed decisions on how best to use this capacity in the current health care system. While this literature is emerging, very little is collected from clinical settings where the large majority of MSK care occurs. The lack of clinically collected data creates gaps in patient-centred research and difficulties with knowledge implementation in treatment settings.

To help bridge this divide, countries such as the United Kingdom, Canada, Sweden, and Australia have established MSK-focused practice-based research networks (PBRNs). PBRNs are sustained collaborations between practitioners and academicians. This collaboration allows patient recruitment from diverse clinical settings and allows practitioners to be more actively involved in the research process. As a result data collected, and subsequent recommendations may have greater clinical utility than that which comes from more traditional research-only settings.

This study aims to develop a MSK focused PBRN within the Swiss chiropractic setting and describe the characteristics of clinicians recruited. It represents a collaborative effort of international researchers, Swiss chiropractic clinicians, and the chiropractic patient and clinical associations in Switzerland (Pro Chiropractic Switzerland and ChiroSuisse). Clinicians will endorse participation in the PBRN by completing an electronic study form. Once established, nested sub-studies will be conducted within this new clinical research environment. Through stakeholder engagement and institutional support, the Swiss ChiCo PBRN can serve as an important resource to advance chiropractic and MSK health services research.

Eligibility Criteria:
Inclusion Criteria:

* Active clinician members of the Swiss Chiropractic Association (ChiroSuisse)
Pregnancy Women and Individual Oral Prophylaxis in the Control of Gingival Inflammation (PRE-IOP)

Gingivitis in pregnant women is a common inflammatory periodontal disease that appears from the third month of pregnancy with an overall prevalence of 35 to 100%. This condition is induced by oral biofilm and exacerbated by increased levels of sex steroid hormones characteristic of pregnancy. Strict bacterial plaque control with both professional and home oral hygiene is essential. Manual toothbrushes require a more specific manual technique for women, while sonic electric toothbrushes, due to their ease of use, might be an excellent for oral individual prophylaxis. Therefore, the question of which type of manual or electric toothbrush might be more effective in reducing gingival inflammation in pregnant women is still unresolved. In literature there are a large number of in vitro clinical studies on this topic, there are currently no clinical studies investigating this long-term clinical comparison.

In this context, this study is a randomized clinical trial consisting of a comparative evaluation between two manual and two sonic electric toothbrushes in the efficacy of the control of plaque in order to reduce gingivitis in women during the period of pregnancy.


Eligibility Criteria:
Inclusion Criteria:

* Female, 18 to 40 years of age
* 15-18 weeks pregnant
* Acceptance of study terms and conditions
* Signature of informed consent form

Exclusion Criteria:

* Protected women
* Stage II,III periodontal disease (i.e. PD ≥ 4 mm, and/or CAL ≥ 4 mm), generalized (\>30% od sites)
* History or treatment of periodontal disease
* Current dental or orthodontic treatment
* Fewer than 20 natural teeth, excluding third molars
* Taking medication affecting the gums and/or oral mucosa
* Regular use (more than once a week) of interdental brushes and/or dental floss and/or mouthwash
* Removable prosthesis
* Dental implants
* Systemic disorder such as blood disorders, diabetes, and risk of endocarditis infections
* Anticoagulant treatment
* Inability to follow protocol or non-cooperation
Comparing Exercise Programs for Managing Knee Osteoarthritis

The goal of this clinical trial is to assess and compare the effectiveness of three different exercise modalities-whole-body vibration exercise, progressive resistance exercise, and home-based exercise -in improving quadriceps isometric muscle strength, physical function, balance, knee pain, osteoarthritis symptoms, and overall quality of life in individuals with knee osteoarthritis.

The main questions it aims to answer are:

* How do WBV, PRE, and home-based exercise compare in improving quadriceps strength in people with knee osteoarthritis?
* Which exercise modality leads to the greatest improvements in physical function, balance, knee pain, and quality of life?

Researchers will compare the three exercise regimens to determine which is most effective for improving knee function and relieving osteoarthritis symptoms.

Participants will:

* Engage in whole-body vibration exercise, progressive resistance exercise, or home-based exercise for 3 weeks.
* Undergo assessments before and at the end of the exercise program, including tests for physical function and balance (Timed Up and Go Test, 5x Sit to Stand Test) and questionnaires to evaluate knee osteoarthritis symptoms (WOMAC), quality of life (SF-36), and self-reported knee pain (Numeric Rating Scale).


Eligibility Criteria:
Inclusion Criteria:

1. participants between the ages of 45-70,
2. diagnosed with knee osteoarthritis according to ACR criteria (unilateral or bilateral),
3. having grade 2 or 3 tibiofemoral knee osteoarthritis according to Kellgren-Lawrence staging,
4. having knee pain due to OA for a minimum of 3 months prior to enrollment,
5. patients whose medical treatment is not expected to change during the study period.

Exclusion Criteria:

1. having or had undergone knee surgery,
2. patients unable to walk without support,
3. having musculoskeletal limitations that prevent participation in resistance exercises (contracture, fracture, etc.),
4. other neurological, cardiac, respiratory and systemic diseases that will affect physical activity,
5. currently implementing a regular exercise or physical therapy program specific to knee OA
A Group Study on the Effects of a Short Multi-Domain Cognitive Training in Healthy Elderly Italian People

Alongside physiological cognitive ageing, nowadays there is an alarming increase in the incidence of dementia that requires communities to invest in its prevention. The engagement in cognitively stimulating activities and strong social networks have been identified among those protective factors promoting successful cognitive ageing. One aspect regarding cognitive stimulation concerns the relevance of the frequency of an external intervention. For these reasons, the aim of this study was to evaluate the efficacy of a 3-month multi-domain cognitive training program, administered once per week in a group of healthy elderly aged over 60 years old. Their results obtained on a series of neuropsychological tests, both pre- (t0) and post-training (t1), were compared with those of a passive control group who did not receive the cognitive training.

Participants were assigned to the experimental or control group based on their time of application to the program. Both experimental and control group underwent a neuropsychological assessment to investigate different cognitive domains, before and after (\~3 months) the training program. Based on the scores obtained during the preliminary neuropsychological assessment, the participants of the experimental training group were divided into small subgroups (ranging from 8 to 12 subjects) to further address individualization of training (i.e. level of difficulty of the exercises proposed). The experimental group attended weekly sessions of the multi-domain cognitive training. Each session lasted around one hour and the overall duration of the training was of 3 months, for a total of 13 sessions. To promote improvement transfer to everyday life, some of the exercises proposed were ecological in their nature, in that, they asked participants to solve tasks that recalled everyday situations (such as remembering names or road maps). Furthermore, throughout the training, approximately once every two sessions brief psycho-educational interventions were provided.

Eligibility Criteria:
Inclusion Criteria:

* Age over 60 years

Exclusion Criteria:

* Negative anamnesis for neurological and/or psychiatric diseases
* No suspected cognitive impairment as assessed during the pre-training neuropsychological testing (\>2 pathological scores)